Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proteogenomics | 6 | 2023 | 87 | 2.300 |
Why?
|
| Breast Neoplasms | 23 | 2024 | 15694 | 1.220 |
Why?
|
| Triple Negative Breast Neoplasms | 5 | 2024 | 1215 | 0.880 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2019 | 129 | 0.810 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2020 | 69 | 0.720 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2018 | 66 | 0.640 |
Why?
|
| DNA Glycosylases | 1 | 2018 | 93 | 0.630 |
Why?
|
| Endonucleases | 1 | 2018 | 178 | 0.600 |
Why?
|
| Calcium-Binding Proteins | 1 | 2018 | 545 | 0.530 |
Why?
|
| Antigens, CD | 1 | 2020 | 1385 | 0.520 |
Why?
|
| Antineoplastic Agents, Hormonal | 4 | 2021 | 840 | 0.500 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 1048 | 0.460 |
Why?
|
| Proteome | 4 | 2023 | 561 | 0.440 |
Why?
|
| Estrogen Receptor alpha | 4 | 2023 | 701 | 0.430 |
Why?
|
| Mycobacterium tuberculosis | 3 | 2012 | 426 | 0.410 |
Why?
|
| Proteomics | 3 | 2022 | 1380 | 0.400 |
Why?
|
| Protein Folding | 1 | 2011 | 281 | 0.380 |
Why?
|
| Aromatase Inhibitors | 4 | 2022 | 305 | 0.370 |
Why?
|
| Bacterial Proteins | 3 | 2012 | 1029 | 0.360 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2022 | 5178 | 0.350 |
Why?
|
| Receptors, Estrogen | 7 | 2024 | 2086 | 0.340 |
Why?
|
| Cell Cycle Proteins | 1 | 2018 | 2045 | 0.340 |
Why?
|
| Drug Delivery Systems | 2 | 2012 | 669 | 0.330 |
Why?
|
| DNA-Binding Proteins | 2 | 2019 | 4821 | 0.330 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2009 | 192 | 0.320 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2019 | 198 | 0.310 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2023 | 4757 | 0.290 |
Why?
|
| Neurofibromin 1 | 3 | 2023 | 85 | 0.270 |
Why?
|
| Proteins | 1 | 2011 | 1963 | 0.230 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2022 | 62 | 0.220 |
Why?
|
| Computational Biology | 1 | 2009 | 1271 | 0.220 |
Why?
|
| MCF-7 Cells | 3 | 2020 | 550 | 0.220 |
Why?
|
| Neoadjuvant Therapy | 4 | 2024 | 4975 | 0.220 |
Why?
|
| Carboplatin | 2 | 2022 | 823 | 0.210 |
Why?
|
| Tissue Array Analysis | 2 | 2020 | 760 | 0.200 |
Why?
|
| Receptor, ErbB-2 | 5 | 2024 | 2518 | 0.200 |
Why?
|
| Humans | 31 | 2024 | 261506 | 0.190 |
Why?
|
| Female | 23 | 2024 | 141928 | 0.190 |
Why?
|
| Mass Spectrometry | 1 | 2023 | 702 | 0.190 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2019 | 47 | 0.180 |
Why?
|
| Circulating Tumor DNA | 1 | 2022 | 235 | 0.180 |
Why?
|
| STAT1 Transcription Factor | 1 | 2020 | 156 | 0.180 |
Why?
|
| Multienzyme Complexes | 2 | 2011 | 213 | 0.170 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2019 | 178 | 0.170 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2019 | 206 | 0.170 |
Why?
|
| Quinolines | 1 | 2022 | 383 | 0.170 |
Why?
|
| Gene Expression Profiling | 3 | 2020 | 5159 | 0.170 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2022 | 1216 | 0.160 |
Why?
|
| Immune Tolerance | 1 | 2020 | 403 | 0.160 |
Why?
|
| Gene Regulatory Networks | 2 | 2020 | 677 | 0.160 |
Why?
|
| MutL Proteins | 1 | 2017 | 30 | 0.160 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2022 | 674 | 0.150 |
Why?
|
| Tamoxifen | 2 | 2020 | 876 | 0.150 |
Why?
|
| Antitubercular Agents | 2 | 2011 | 318 | 0.150 |
Why?
|
| Mutation | 6 | 2023 | 15179 | 0.150 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2017 | 126 | 0.150 |
Why?
|
| Trastuzumab | 1 | 2020 | 696 | 0.150 |
Why?
|
| Gene Fusion | 1 | 2018 | 209 | 0.150 |
Why?
|
| Ki-67 Antigen | 3 | 2024 | 666 | 0.140 |
Why?
|
| Up-Regulation | 2 | 2020 | 2450 | 0.140 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 755 | 0.140 |
Why?
|
| Protein Kinases | 2 | 2020 | 874 | 0.140 |
Why?
|
| Interferon-gamma | 1 | 2020 | 1144 | 0.140 |
Why?
|
| Heterografts | 1 | 2018 | 733 | 0.130 |
Why?
|
| Transcriptome | 2 | 2021 | 1859 | 0.130 |
Why?
|
| Prognosis | 6 | 2023 | 21713 | 0.130 |
Why?
|
| Carcinogenesis | 1 | 2020 | 1026 | 0.120 |
Why?
|
| DNA Repair | 2 | 2020 | 1872 | 0.120 |
Why?
|
| Gene Amplification | 1 | 2016 | 731 | 0.110 |
Why?
|
| Cell Proliferation | 3 | 2021 | 7226 | 0.110 |
Why?
|
| Genomic Instability | 1 | 2016 | 519 | 0.110 |
Why?
|
| Protein Interaction Mapping | 2 | 2012 | 162 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 15862 | 0.110 |
Why?
|
| Crowdsourcing | 1 | 2012 | 21 | 0.110 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 1516 | 0.110 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 980 | 0.100 |
Why?
|
| Protein Structure, Quaternary | 1 | 2011 | 138 | 0.100 |
Why?
|
| Subcellular Fractions | 1 | 2011 | 201 | 0.100 |
Why?
|
| Genome, Bacterial | 1 | 2012 | 200 | 0.100 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 1249 | 0.100 |
Why?
|
| Protein Structure, Secondary | 1 | 2011 | 336 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 8873 | 0.090 |
Why?
|
| Antineoplastic Agents | 2 | 2023 | 14289 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 2330 | 0.090 |
Why?
|
| Disease | 1 | 2011 | 165 | 0.090 |
Why?
|
| Postmenopause | 2 | 2024 | 378 | 0.090 |
Why?
|
| Protein Transport | 1 | 2011 | 734 | 0.090 |
Why?
|
| Signal Transduction | 4 | 2020 | 11965 | 0.090 |
Why?
|
| Amino Acids | 1 | 2011 | 728 | 0.080 |
Why?
|
| Biomarkers | 1 | 2019 | 5047 | 0.080 |
Why?
|
| GTP-Binding Proteins | 1 | 2009 | 321 | 0.080 |
Why?
|
| Macrophages | 1 | 2012 | 1304 | 0.070 |
Why?
|
| Biomarkers, Tumor | 2 | 2022 | 10331 | 0.070 |
Why?
|
| Membrane Proteins | 2 | 2022 | 2819 | 0.070 |
Why?
|
| Animals | 5 | 2023 | 59536 | 0.060 |
Why?
|
| Middle Aged | 6 | 2024 | 86204 | 0.060 |
Why?
|
| Cell Nucleus | 2 | 2020 | 1620 | 0.060 |
Why?
|
| Computer Simulation | 1 | 2009 | 1529 | 0.060 |
Why?
|
| Mice | 3 | 2021 | 34495 | 0.060 |
Why?
|
| Mice, Nude | 2 | 2021 | 4307 | 0.060 |
Why?
|
| NFI Transcription Factors | 1 | 2023 | 74 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2023 | 6150 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2020 | 9244 | 0.050 |
Why?
|
| Genomics | 3 | 2020 | 2738 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2021 | 3821 | 0.050 |
Why?
|
| Purines | 1 | 2023 | 273 | 0.050 |
Why?
|
| APOBEC Deaminases | 1 | 2020 | 6 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 371 | 0.050 |
Why?
|
| DNA Damage | 2 | 2020 | 1954 | 0.050 |
Why?
|
| GTP Phosphohydrolases | 1 | 2022 | 336 | 0.050 |
Why?
|
| British Columbia | 1 | 2019 | 24 | 0.050 |
Why?
|
| Datasets as Topic | 1 | 2020 | 181 | 0.050 |
Why?
|
| Co-Repressor Proteins | 1 | 2020 | 122 | 0.040 |
Why?
|
| Triazoles | 1 | 2024 | 617 | 0.040 |
Why?
|
| Nitriles | 1 | 2024 | 906 | 0.040 |
Why?
|
| Retinoblastoma Protein | 1 | 2020 | 335 | 0.040 |
Why?
|
| Amino Acid Motifs | 1 | 2020 | 392 | 0.040 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 2864 | 0.040 |
Why?
|
| Estrogen Antagonists | 1 | 2020 | 184 | 0.040 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2020 | 134 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2020 | 483 | 0.040 |
Why?
|
| Brazil | 1 | 2019 | 165 | 0.040 |
Why?
|
| Class Ia Phosphatidylinositol 3-Kinase | 1 | 2018 | 29 | 0.040 |
Why?
|
| Discoidin Domain Receptor 1 | 1 | 2018 | 16 | 0.040 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2018 | 43 | 0.040 |
Why?
|
| Cell Line, Tumor | 3 | 2020 | 14551 | 0.040 |
Why?
|
| Quinazolines | 1 | 2022 | 923 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2019 | 9180 | 0.040 |
Why?
|
| Immunotherapy | 2 | 2021 | 3341 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2020 | 745 | 0.040 |
Why?
|
| Metabolomics | 1 | 2020 | 478 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2022 | 2232 | 0.040 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2016 | 76 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 521 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2023 | 1154 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2020 | 1869 | 0.030 |
Why?
|
| ras Proteins | 1 | 2020 | 770 | 0.030 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2019 | 436 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2023 | 2022 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 1742 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2022 | 3981 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2020 | 2074 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 5395 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 1519 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2019 | 973 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2019 | 1392 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 10035 | 0.030 |
Why?
|
| Adult | 4 | 2021 | 77950 | 0.030 |
Why?
|
| Transfection | 1 | 2018 | 2944 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 2803 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 1546 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2019 | 2508 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2020 | 4804 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2021 | 2295 | 0.030 |
Why?
|
| Aged | 3 | 2024 | 70117 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2018 | 1678 | 0.030 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2011 | 30 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2017 | 2084 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 6682 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2023 | 32848 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 29902 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2023 | 7222 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2022 | 3552 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2012 | 314 | 0.020 |
Why?
|
| Algorithms | 1 | 2020 | 3890 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2018 | 6100 | 0.020 |
Why?
|
| Drug Discovery | 1 | 2011 | 324 | 0.020 |
Why?
|
| Survival Rate | 1 | 2021 | 12221 | 0.020 |
Why?
|
| Apoptosis | 1 | 2021 | 7591 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 4233 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 6089 | 0.010 |
Why?
|
| Young Adult | 1 | 2021 | 21445 | 0.010 |
Why?
|
| Male | 1 | 2021 | 123000 | 0.010 |
Why?
|